RNTX (Rein Therapeutics) Common Stock: $0.11 Mil (As of Mar. 2026)


RNTX Rein Therapeutics Inc RNTX
29 GF Score
Price $0.97
! 1 Warning Sign
View Full Analysis

What is Rein Therapeutics Common Stock?

Rein Therapeutics RNTX -3.48% 29 Common Stock is $0.11 Mil as of Mar. 2026. GuruFocus rates RNTX with a GF Score™ of 29/100. The stock has 1 warning sign investors should review.

Rein Therapeutics's quarterly common stock increased from Sep. 2025 ($0.11 Mil) to Dec. 2025 ($0.11 Mil) and increased from Dec. 2025 ($0.11 Mil) to Mar. 2026 ($0.11 Mil).

Rein Therapeutics's annual common stock increased from Dec. 2023 ($0.09 Mil) to Dec. 2024 ($0.11 Mil) and increased from Dec. 2024 ($0.11 Mil) to Dec. 2025 ($0.11 Mil).

Rein Therapeutics Common Stock Historical Data

* Premium members only.

The historical data trend for Rein Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rein Therapeutics Common Stock Chart

Rein Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.09 0.09 0.09 0.11 0.11

Rein Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 0.13 0.11 0.11 0.11
RNTX
29GF Score
Rein Therapeutics Inc RNTX
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rein Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.11 Mil mean?
Rein Therapeutics (RNTX) has a Common Stock of $0.11 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Rein Therapeutics and its competitors.
Is Rein Therapeutics' Common Stock too high?
Rein Therapeutics' current Common Stock is $0.11 Mil. Overall, Rein Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Rein Therapeutics' Common Stock compare to IBIO and RANI?
Rein Therapeutics' Common Stock of $0.11 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Rein Therapeutics and its competitors. Rein Therapeutics's current Common Stock is $0.11 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rein Therapeutics stock overvalued right now?
Rein Therapeutics (RNTX) has a current Common Stock of $0.11 Mil. The current Common Stock is $0.11 Mil. Rein Therapeutics' overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Rein Therapeutics (RNTX), the current Common Stock is $0.11 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rein Therapeutics Business Description

Address 12407 North Mopac Expressway, Suite 250, No.390, Austin, TX, USA, 78758
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
29GF Score

Get the complete analysis for RNTX

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.97
Price